Aggiornamento 1 di 1UltimoGiorno 1
Six Against the Scientists: An FDA Panel Backs Peptides With No Clinical Track Record
A two-day meeting in Washington ended with a narrow recommendation to loosen compounding rules for unapproved compounds championed by influencers and RFK Jr. — over the objections of the agency's own staff.
Cosa sapevamo all'inizio
- An FDA advisory committee voted to recommend six peptides for the 503A compounding list over the objections of agency career scientists.
- NBC's count of four peptides endorsed is the lone outlier against six outlets reporting six.
Allora ancora aperto
- Whether the FDA will adopt the committee's recommendation in full or in part.
- Which specific peptides failed to win a majority, given the gap between seven on the agenda and six (or four) endorsed.
Cosa avevamo detto di seguire
- The agency's formal rulemaking docket, and whether HHS pushes the timeline forward or lets it drift through 2027.
